Prognostic impact of interleukin‑6 and C‑reactive protein on patients with breast cancer

  • Authors:
    • Tatsuo Shimura
    • Masahiko Shibata
    • Kenji Gonda
    • Yuko Murakami
    • Masaru Noda
    • Kazunoshin Tachibana
    • Noriko Abe
    • Tohru Ohtake
  • View Affiliations

  • Published online on: March 21, 2019     https://doi.org/10.3892/ol.2019.10183
  • Pages: 5139-5146
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The prognostic impacts of preoperative C‑reactive protein (CRP) and interleukin (IL)‑6 expression levels in patients with breast cancer remain controversial. A total of 55 female patients with invasive breast cancer were enrolled, and preoperative prognostic parameters including IL‑6 and CRP were analyzed. Overall survival (OS) and recurrence‑free survival (RFS) were estimated using the Kaplan‑Meier method, and candidates' prognostic factors were examined using a Cox proportional hazard model. Using receiver operating characteristic curve analysis, IL‑6 at 10.0 pg/ml and CRP at 0.12 mg/dl were determined as threshold values to predict OS and RFS, respectively. Patients with IL‑6 ≥10.0 pg/ml had poorer OS compared with those with IL‑6 <10.0 pg/ml (P=0.003), and patients with CRP ≥0.12 mg/dl had poorer RFS compared with those with CRP <0.12 mg/dl (P<0.001). Serum IL‑6 level (hazard ratio, 13.230; 95% confidence interval, 1.285‑136.214; P=0.030) and triple‑negative subtype (hazard ratio, 11.739; 95% confidence interval, 1.415‑97.362; P=0.023) were independent prognostic factors for OS, and CRP expression level was an independent prognostic factor for RFS in patients with breast cancer (hazard ratio, 18.571; 95% confidence interval, 2.240‑153.949; P=0.007). In patients with invasive breast cancer, preoperative serum IL‑6 and triple‑negative subtype may be independent prognostic factors for OS, while for RFS, preoperative CRP may be a more accurate prognostic factor compared with those currently established.
View Figures
View References

Related Articles

Journal Cover

June 2019
Volume 17 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Shimura, T., Shibata, M., Gonda, K., Murakami, Y., Noda, M., Tachibana, K. ... Ohtake, T. (2019). Prognostic impact of interleukin‑6 and C‑reactive protein on patients with breast cancer. Oncology Letters, 17, 5139-5146. https://doi.org/10.3892/ol.2019.10183
MLA
Shimura, T., Shibata, M., Gonda, K., Murakami, Y., Noda, M., Tachibana, K., Abe, N., Ohtake, T."Prognostic impact of interleukin‑6 and C‑reactive protein on patients with breast cancer". Oncology Letters 17.6 (2019): 5139-5146.
Chicago
Shimura, T., Shibata, M., Gonda, K., Murakami, Y., Noda, M., Tachibana, K., Abe, N., Ohtake, T."Prognostic impact of interleukin‑6 and C‑reactive protein on patients with breast cancer". Oncology Letters 17, no. 6 (2019): 5139-5146. https://doi.org/10.3892/ol.2019.10183